

## 5 . 業績等一覽

1. Ko K, Nagashima S, E B, Ouoba S, Akita T, Sugiyama A, Ohisa M, Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Kishita E, Kuwabara M, Takahashi K, Tanaka J, Molecular Characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan, Plos One, 2021; 5(16): e0246383.
2. \_\_\_\_\_ challenge!  
Vol. 58, 2020 11 , p16
3. \_\_\_\_\_ AMED  
-  
No. 70 2020 10 15 p1-2
4. Nomura T, Nazmul T, Yoshimoto R, Higashiura A, Oda K, Sakaguchi T. Ethanol susceptibility of SARS-CoV-2 and other enveloped viruses. Biocontrol Science, in press.
5. \_\_\_\_\_ Octadecyl dimethyl (3-triethoxysilylpropyl) ammonium chloride (SARS-CoV-2)  
2021, 78, in press.
6. \_\_\_\_\_ pp. 117-123
7. Kitagawa H, Nomura T, Nazmul T, Kawano R, Omori K, Shigemoto N, Sakaguchi T, Ohge H. Effect of intermittent irradiation and dose-response of 222 nm ultraviolet light on SARS-CoV-2 contamination. Photodiagnosis and Photodynamic Therapy 2021, 33, 102184.
8. Kitagawa H, Nomura T, Ohge H, Nazmul T, Omori K, Shigemoto N, Sakaguchi T. Effectiveness of 222-nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination. American Journal of Infection Control 2021, 49, 299-301.
9. \_\_\_\_\_ PCR  
SARS-CoV-2 2021, 78, 275-280.
10. \_\_\_\_\_  
2021, 93, 102-107.
11. Ko Ko, Nagashima S, Bunthen E, Serge O, Akita T, Sugiyama A, Ohisa M

Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Kishita E, Kuwabara M, Takahashi K, Tanaka J. Molecular Characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan. PLOS ONE 2021, 16, e0246383.

12. \_\_\_\_\_, \_\_\_\_\_, \_\_\_\_\_ - \_\_\_\_\_  
ICT 2021, 16, 58-63.
13. \_\_\_\_\_ P3  
SARS-CoV-2 99 2020 12 , 12-13.
14. \_\_\_\_\_ Activities  
Hiroshima University BioMed News 4 2020 11 , p 3.
15. \_\_\_\_\_  
1 2 No. 598 2020 8
16. \_\_\_\_\_ ( )  
Power Mook 28
17. \_\_\_\_\_ 2020 4  
No. 648 p 7-11.
1. \_\_\_\_\_  
Web 2021 1 22
2. \_\_\_\_\_ 104  
59 2020  
11 15
3. \_\_\_\_\_ FT Web DAY1  
C-1 2020 11 6
4. \_\_\_\_\_ COVID-19 1  
35  
2020 9 19 20
5. Tanuza Nazmul \_\_\_\_\_ Ethanol sensitivity of SARS-  
CoV-2 35 2020 9  
19 20
6. \_\_\_\_\_ 35  
SARS-CoV-2 2020 9 19 20

7. \_\_\_\_\_ SARS-CoV-2 S  
35  
2020 9 19 20
8. \_\_\_\_\_  
\_\_\_\_\_  
95 69
9. \_\_\_\_\_ J-SPEED AI  
26 9 ICT AI  
2021 3 17
10. \_\_\_\_\_  
J-SPEED 26  
3 2021 3 16
11. \_\_\_\_\_  
24 25  
2021 2 21
12. Hidetoshi TAHARA, EVs derived small non-coding RNAs as biomarker and COVID-19 test in Japan, ISEV( ), EVTalk, 2020 8 20
1. \_\_\_\_\_ SARS-CoV-2 Ortho  
Clinical Diagnostics Web 2021 3 26
2. \_\_\_\_\_  
2021 2 24
3. \_\_\_\_\_ 2  
2021 2 6
4. \_\_\_\_\_ CDC  
2020 4 9
5. \_\_\_\_\_  
Web 2021 1 19
6. \_\_\_\_\_  
11 2020 11 18
7. \_\_\_\_\_  
2020 9 26
8. \_\_\_\_\_  
2020 7 14

9. \_\_\_\_\_ SARS-CoV-2  
2020 7 20
10. \_\_\_\_\_ SARS-CoV-2 What changed our daily life.  
2020 7 2
11. \_\_\_\_\_ SARS-CoV-2 6  
2020 4 8
12. \_\_\_\_\_ J-SPEED 17  
2021 4 19
13. \_\_\_\_\_ COVID-19  
19 2021 3 17
14. \_\_\_\_\_ - DX  
2021 3 5
15. \_\_\_\_\_  
2020  
2021 1 26
16. Tatsuhiko Kubo, Japan Disaster Relief Infectious Diseases Response Team. WHO Emergency Medical Team Highly Infectious Diseases Technical Working Group. 8th December 2020.
17. Tatsuhiko Kubo, EMF Minimum Data Set (MDS) for COVID-19. ASEAN The ARCH Project 2nd Webinar on Good Practice on Medical Response Against COVID-19 Outbreak 7th October 2020.
18. Tatsuhiko Kubo, Phumin Silapunt. The ARCH Project and its approach to establish an academic network of H-EDRM. WHO Health EDRM Research Network Core Group Meeting. 27th November 2020.
19. \_\_\_\_\_ COVID-19
20. \_\_\_\_\_ 2020 10 25
21. \_\_\_\_\_ 2  
2020 10 5 F
22. \_\_\_\_\_  
2020 9 19
23. Tatsuhiko Kubo, Introducing the WHO Emergency Medical Team Minimum Data Set (MDS). The ASEAN Emergency Operation Center NETWORK. 18th August 2020.

24. \_\_\_\_\_ /J- COVID-19  
 27  
 25. \_\_\_\_\_ COVID-19  
 19 2021 3 17  
 26. \_\_\_\_\_  
 2020  
 2021 1 26

1. 2021 2 17 2021-022249 \_\_\_\_\_  
 2. 2021 1 22 2021-008575  
 3. 2020 11 17 2020-191046 COVID-19  
 \_\_\_\_\_

Aenti Therapeutics, Inc.  
 4. 2020 6 18 2020-105638  
 \_\_\_\_\_

1. \_\_\_\_\_ \_\_\_\_\_ \_\_\_\_\_ \_\_\_\_\_ \_\_\_\_\_ \_\_\_\_\_ 2021/04/28 TSS  
 NHK  
 2. \_\_\_\_\_ 2021 04 15 NHK  
 3. \_\_\_\_\_ 2021 04 02 NHK  
 4. \_\_\_\_\_ 2021 02 18 NHK  
 5. \_\_\_\_\_ 2021 02 13 NHK  
 6. \_\_\_\_\_ 2021 01 20 RCC  
 7. \_\_\_\_\_ \_\_\_\_\_ 2020 12 75

8.	_____	2020	12	03	NHK			
9.	_____	2020	10	30		0.13%		
10.	_____	2020	10	30			0.13%	
11.	_____	2020	10	30			0.13%	
12.	_____	2020	10	30		0.13%	1	
13.	_____	2020	10	30		0.13%		
14.	_____	2020	10	30	RCC			
						0.13%		
15.	_____	2020	9	2				
16.	_____	2020	8	23	TSS		.	
17.	_____	2020	8	10				
18.	_____	2020	8	5				
19.	_____	2020	8	3				
20.	_____	Proposal for the establishment of an EGYPTIAN CENTRE FOR DISEASE PREVENTION AND CONTROL(EGY-CDC)						
		CDC				2020	6	18
								Web
21.	_____	COVID-19 online conference with Uzbekistan Embassy						
								2020
								6
		18						Web
22.	_____	2021	3	12	Web		NETIB-NEWS	
23.	_____	2021	3	9				
					NHK			
24.	_____	2021	3	8				
						IB		10-11
25.	_____	2021	3	5				

26.	_____	2021	3	5	FunFANFun	
27.	_____	2021	2	22		2021
28.	_____	2021	2	24		
	PCR					
29.	_____	2021	2	23	RCC	
30.	_____	2021	2	18		
31.	_____	2021	2	18		
32.	_____	2021	2	17	NHK	
33.	_____	2021	2	17		
34.	_____	2021	2	10	RCC	
35.	_____	2021	1	28		
36.	_____	2021	1	28		PCR
37.	_____	2021	1	20		80
	PCR					
38.	_____	2021	1	17		
39.	_____	2021	1	8		
40.	_____	2021	1	5	News Zero	
41.	_____	2021	1	4		
42.	_____	2020	12	24	News Zero	
43.	_____	2020	12	21	News Zero	

44.	_____	2020	11	12			5up!
45.	_____	2020	11	10			5up!
46.	_____	2020	10	27	AP		SARS-CoV-2
47.	_____	2020	10	20			
						99.99%	
48.	_____	2020	10	7			74
49.	_____	2020	10	6			
						99.99%	
50.	_____	2020	8	21			5up!
51.	_____	2020	8	7			10
	500						
52.	_____	2020	8	6	TSS		
53.	_____	2020	7	10			30
54.	_____	2020	7	1			5 up!
55.	_____	2020	6	27			
56.	_____	2020	6	16	NHK		
57.	_____	2020	6	16			2020 8
58.	_____	2020	6	15			Lush Fresh Handmade
	Cosmetics						3
59.	_____	2020	5	29			
60.	_____	2020	5	23			
61.	_____	2020	5	16			
62.	_____	2020	5	1			

1000

63. \_\_\_\_\_ 2020 4 29

...

64. \_\_\_\_\_ 2020 4 24

65. \_\_\_\_\_ 2020 4 17

66. \_\_\_\_\_ 2020 4 6 FM  
Campus

Radio

67. \_\_\_\_\_ 2021

68. \_\_\_\_\_ 2021/02/17 ( ) 18 00 NHK

69. \_\_\_\_\_ 2020/12/31 ( ) RCC RCC

広島県・広島大学

官学連携による COVID-19 の検査研究体制構築業務 報告書

2021 年 4 月 30 日発行

大学院医系科学研究科	疫学・疾病制御学	教授	田中純子
大学院医系科学研究科	ウイルス学	教授	坂口剛正
大学院医系科学研究科	細胞分子生物学研究室	教授	田原栄俊
大学院医系科学研究科	公衆衛生学	教授	久保達彦
大学病院	感染症科	教授	大毛宏喜
大学院医系科学研究科	消化器・移植外科学	教授	大段秀樹